Last reviewed · How we verify
Tarceva, erlotinib, OSI-774
Tarceva, erlotinib, OSI-774 is a Small molecule drug developed by OSI Pharmaceuticals. It is currently in Phase 1 development.
At a glance
| Generic name | Tarceva, erlotinib, OSI-774 |
|---|---|
| Sponsor | OSI Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (PHASE1)
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (PHASE1)
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tarceva, erlotinib, OSI-774 CI brief — competitive landscape report
- Tarceva, erlotinib, OSI-774 updates RSS · CI watch RSS
- OSI Pharmaceuticals portfolio CI
Frequently asked questions about Tarceva, erlotinib, OSI-774
What is Tarceva, erlotinib, OSI-774?
Tarceva, erlotinib, OSI-774 is a Small molecule drug developed by OSI Pharmaceuticals.
Who makes Tarceva, erlotinib, OSI-774?
Tarceva, erlotinib, OSI-774 is developed by OSI Pharmaceuticals (see full OSI Pharmaceuticals pipeline at /company/osi-pharmaceuticals).
What development phase is Tarceva, erlotinib, OSI-774 in?
Tarceva, erlotinib, OSI-774 is in Phase 1.
Related
- Manufacturer: OSI Pharmaceuticals — full pipeline